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Abstract
Background: Hemophilia A is a bleeding disorder caused by deficiency in coagulation factor VIII. Recombinant
factor VIII (rFVIII) is an alternative to plasma-derived FVIII for the treatment of hemophilia A. However, commercial
manufacturing of rFVIII products is inefficient and costly and is associated to high prices and product shortage,
even in economically privileged countries. This situation may be solved by adopting more efficient production
methods. Here, we evaluated the potential of transient transfection in producing rFVIII in serum-free suspension
HEK 293 cell cultures and investigated the effects of different DNA concentration (0.4, 0.6 and 0.8 μg/10
6 cells) and
repeated transfections done at 34° and 37°C.
Results: We observed a decrease in cell growth when high DNA concentrations were used, but no significant
differences in transfection efficiency and in the biological activity of the rFVIII were noticed. The best condition for
rFVIII production was obtained with repeated transfections at 34°C using 0.4 μg DNA/10
6 cells through which
almost 50 IU of active rFVIII was produced six days post-transfection.
Conclusion: Serum-free suspension transient transfection is thus a viable option for high-yield-rFVIII production.
Work is in progress to further optimize the process and validate its scalability.
Background
Hemophilia A is a bleeding disorder caused by a defi-
cient coagulation factor VIII (FVIII) that affects one in
5,000 to 10,000 males. Treatment for hemophilia A
patients consists of replacement therapy using human
plasma-derived FVIII (pdFVIII) or recombinant FVIII
(rFVIII). Although effective, the pdFVIII replacement
therapy has some drawbacks such as limited availability
and the risk of transmitting blood-borne diseases to
patients [1]. Recombinant factor VIII (rFVIII) emerges
as an alternative to pdFVIII for the treatment of hemo-
philia A. However, efficient production of human rFVIII
has been shown to be difficult [2-4]. The rFVIII expres-
sion levels are significantly lower than those of other
recombinant proteins comparable in structure, size, and
complexity [3]. Also, the expression is two or three
orders of magnitude lower than other recombinant pro-
teins produced with similar strategies [2]. This may be
due to a low rFVIII mRNA level, a very inefficient trans-
port of the primary translation product, and poor FVIII
cellular secretion [5-7]. Some progress has been made
towards recognizing the bottlenecks in FVIII biosynth-
esis, which primarily occur in the endoplasmic reticulum
[8,9].
rFVIII is exclusively produced in cultured mammalian
cells such as baby hamster kidney or Chinese hamster
ovary cells, using large-scale bioreactors. Several techni-
q u e sa r eu s e dt om a x i m i z ep r o d u c t i o n .T h e s ei n c l u d e
amplification of the FVIII transgene using dihydrofolate
reductase/methotrexate selection, addition of FVIII sta-
bilizing agents such as bovine/human albumin, or co-
expression of the von Willebrand factor (vWf), and use
of continuous-perfusion fermentation to maximize cell
growth, cell density, and product recovery [4].
This has led to rather inefficient commercial rFVIII
manufacturing and, in turn, important limitations
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cost and low availability that even led to product short-
age in economically privileged countries [10,11]. This
situation may be solved by adopting more efficient and
effective production methods [10].
Large-scale transient transfection is an efficient tech-
nology for the fast production of significant amounts of
recombinant proteins [12,13] and it may represent an
ingenious alternative for rFVIII production. Further-
more, scalable transient expression is an extremely effec-
tive technique for rapid screening of functional
therapeutic candidate cell clones and subsequent manu-
facturing [13].
In this study we investigated, for the first time, the
potential of transient transfection in producing rFVIII in
serum-free suspension HEK 293 cell cultures. Through
transfection using the polycationic polymer polyethyleni-
mine (PEI) at high cell density, we were able to produce
active rFVIII of up to 0.6 IU/mL within 4 days after
transfection using a scalable system. After optimization
of the production conditions, we were able to produce
49.3 IU of active rFVIII (120 mL of culture volume)
within only 6 days after transfection.
Methods
Cell and Culture Media
A HEK293SF-3F6 cell line originally developed for the
production of adenoviral vectors was used [14]. This
clone has been selected for high-yield production in sus-
pension and serum-free media. Additionally, a master
cell bank is available for manufacturing of clinical mate-
rial. The cell line presents great transfection potential
and it grows in suspension under serum-free conditions.
The cell line was cultured in HyQSFM4TransFx293
(HyQ) (Hyclone, Logan, UT, USA), a commercial med-
ium specially developed for the transfection of HEK293
cells, supplemented with 5% Cell Boost 5 (CB5,
Hyclone).
Transient Transfection
T h ec o n s t r u c t su s e di nt h i ss t u d yw e r eb a s e do nt h e
replication-deficient bicistronic lentiviral vector cPPT-C
(FVIIIdelB)IGWS, which codes for human B-domain
deleted FVIII(FVIIIdelB), the deleted region of B domain
was from from 2428 to 5067 nucleotides (full-length
FVIII-cDNA accession number K01740) and this vector
has the IRES element followed by the enhanced green
fluorescent protein (EGFP). Our lentiviral vector has the
CMV promoter, cPPT (central Polypurine Tract) from
t h eH I V - 1i n t e g r a s eg e n et h a ti n c r e a s e st h ec o p yn u m -
ber of lentivirus integrating into the host genome, thus
increasing viral titer and also the WPRE (Woodchuck
Posttranscriptional Regulatory Element) from the wood-
chuck hepatitis virus that increases transgene
expression. A more detailed vector description can be
found in Tonn et al. [15].
The transfection protocol has been published pre-
viously [16]. Pre-cultures underwent passages every 2-3
days to keep the cells in their exponential growth phase.
A few hours before transfection, the cell suspension was
centrifuged (300 g for 5 min) and re-suspended in fresh
medium at 5 × 10
6 cell/mL.
Because of the instability of rFVIII, we conducted daily
harvests and completed medium exchange by centrifu-
gation (300 g for 5 min), starting 1 day post-transfec-
tion, in 125 mL Erlenmeyer flasks containing 20 mL of
working volume. rFVIII-containing harvests were filtered
through 0.45 μm HT Tuffryn membranes (Pall, Ann
Arbor, MI, USA) to remove cell debris and were stored
at -80°C until further analyses.
To determine the best transfection parameters for
rFVIII production, three different DNA concentrations
(0.4, 0.6, and 0.8 μgD N A / 1 0
6 cells) were tested at 37°C.
The potential of repeated transfections at three different
times (0, 48, and 96 hours post-inoculation) and two
different temperatures (34 and 37°C) were also tested. In
the repeated transfection experiments, a new amount of
polyplexes was added at 48 and 96 hours, besides the
amount added in the beginning of the experiment. In
this case, the amount of polyplexes was corrected based
on the cell density determined in each culture time.
Analytical Methods
Hemacytometer counts using e r y t h r o s i n eBd y ee x c l u -
sion were used to assess cellular density and viability.
Glucose, lactate, and ammonia concentration assess-
ment were performed using Biolyser Analyser (Kodak,
New Haven, CT). Amino acid concentration in fresh
media and supernatants were quantified by HPLC
(Waters Alliance System, Waters Corp., Milford, MA)
using a modification of the Waters AccQ-Tag™ method
as described by Cohen (2000).
The commercial ELISA kit Asserachrom FVIII:C Ag
(Diagnostica Stago) was used to quantify the rFVIII pro-
duction. To determine the rFVIII activity, we used the
chromogenic kit COAMATIC
® Factor FVIII (Chromo-
genix, Instrumentation Laboratory SpA). Both kits were
used according to manufacturer’s instructions.
Results
Effect of DNA Concentration
For an initial evaluation of the potential of transient
transfection on rFVIII protein production, transfections
using different DNA concentrations were performed.
High-density HEK293 cell cultures (5 × 10
6 cells/mL)
were transfected with 0.4, 0.6, and 0.8 μg DNA/10
6 cells
at PEI:DNA ratio of 2:1. Figure 1A shows that an
increased concentration of PEI:DNA complex (polyplex)
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Page 2 of 10Figure 1 High-density transfection of Hek293 cells. Cells were re-suspended in 20 mL of fresh HyQSFM4TransFx293 medium to a final
density of 5 × 10
6 cells/mL and transfected with 2, 3, and 4 μg of DNA and 4, 6, and 8 μg of PEI, respectively, in 125 mL Erlenmeyer flask and
37°C. a: total cell density and viability; b: rFVIII activity measured by chromogenic assay; and c: rFVIII measured by ELISA. Values shown are the
averages (mean ± SEM) of the duplicated samples from one representative experiment.
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decrease significantly when using DNA concentrations
of 0.6 and 0.8 μgD N A / 1 0
6 cells, we observed a large
amount of cellular debris. After 96 hours of culture, the
transfection efficiency was approximately 50% for all
DNA concentrations and conditions tested (Table 1).
The biological activity of the rFVIII produced using
DNA concentrations of 0.6 and 0.8 μgD N A / 1 0
6 cells
was similar but slightly higher than the one obtained
using 0.4 μgD N A / 1 0
6 cells in the first 2 days post-
transfection (Figure 1B). A larger difference was
observed by ELISA quantification (Figure 1C). After 4
days of transfection, 200, 109, and 49 ng/mL of rFVIII
were produced with DNA concentrations of 0.4, 0.6,
and 0.8 μgD N A / 1 0
6 cells, respectively. The DNA con-
centration of 0.6 μg DNA/10
6 cells produced the highest
amount of cumulative active rFVIII (35.1 IU) when
comparing with 0.4 and 0.8 μgD N A / 1 0
6 cells. The cell-
specific rFVIII production rate was also higher using 0.6
μgD N A / 1 0
6 cells for single transfections, as shown in
Table 1.
To apply a repeated transfection strategy, we hypothe-
sized that the “quality” of the culture, i.e. a high number
of viable cells in a good physiological state is a critical
parameter; we thus decided to use the concentration of
0.4 μgD N A / 1 0
6 cells in the following experiments.
Despite the lower rFVIII specific activity obtained in
this condition, the cell viability remained high, no cellu-
lar debris was observed and a higher amount of protein
was quantified by ELISA while consuming the lowest
amount of DNA.
Effect of Temperature and Repeated Transfection
The potential of repeated transfections at low tempera-
ture was also evaluated. Figure 2A shows the cellular
growth and rFVIII production at 34°C and 37°C. Transi-
ent transfections were done at 0, 48, and 96 hours after
inoculation. At 34°C, no cellular growth was observed
but cells remained viable, even after re-transfecting
them. The repeated transfection at 37°C had an inhibi-
tory effect on cell growth. After the second round of
transfection (48 hours after inoculation) a large amount
of cellular debris was observed, and total cell concentra-
tion declined significantly after 72 hours (Figure 2A).
The percentage of GFP-positive cells was measured at
48, 72, 96, and 120 hours after cell inoculation and
remained in the range of 50-60% for both temperatures
tested (34°C and 37°C).
Interestingly, the rFVIII produced at 34°C presented a
higher biological activity than that observed at 37°C. At
this temperature we were able to produce 0.64 IU/mL
of active rFVIII 96 hours after inoculation through two
rounds of transfections. In contrast, production at 37°C
resulted in approximately 2-fold decrease in active
rFVIII (0.33 IU/mL). Nevertheless, the kinetics for total
rFVIII production (determined by ELISA) was similar. A
significant difference between the two production tem-
peratures tested was observed at 144 hours (393 ng/mL
at 34°C against 50.5 ng/mL at 37°C).
Consequently, the cell-specific rFVIII production rate
was 26% higher at 34°C when compared to production
at 37°C (0.58 ngFVIII/10
6cell.h against 0.43 ngFVIII/
10
6cell.h) (Table 1). After 144 hours of transfection, 49.3
IU of active rFVIII at 34°C and 21.9 IU at 37°C were
produced.
Complete replacement of the culture medium simu-
lated a perfusion operation and prevented nutrient
exhaustion and accumulation of inhibitory by-products
(Figure 3). Even with high cell concentrations we did
not observe the depletion of glucose and glutamine or
the formation of toxic by-products that could potentially
inhibit cell growth. Nevertheless, complete replacement
of the culture medium provides a higher production of
active FVIII as can be seen by comparing the levels
obtained in batch mode (Figure 4) with those obtained
in Figures 1 and 2. When the medium was not changed,
the expression of rFVIII was lower than what was
achieved through simulation of perfusion mode opera-
tion (up to 400 ng/mL or 0.6 IU/mL). In batch mode,
no significant rFVIII biological activity was detected
until 96 hours post-transfection but even then the levels
were much lower (0.2 IU/mL).
Table 1 Effect of transfection conditions on transfection efficiency, cumulative rFVIII production, and cell specific rFVIII
production (qFVIII) rate by transient transfection of HEK293 suspension cultures
Condition Transfection efficiency (%) *Cumulative active rFVIII production (IU) qFVIII
(ng FVIII/10
6 cell.h)
0.4 μg DNA/10
6 cel 51.1 25.4 0.24
0.6 μg DNA/10
6 cel 50.0 35.1 0.30
0.8 μg DNA/10
6 cel 55.9 29.6 0.21
0.4 μg DNA/10
6 cel
37°C Repeated Transfection
57.3 21.9 0.43
0.4 μg DNA/10
6 cel
34°C Repeated Transfection
52.8 49.3 0.58
The transfections were done using the PEI:DNA ratio of 2:1. *rFVIII cumulative production in IU was calculated using biological activity results.
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Page 4 of 10Figure 2 High-density transfection of Hek293 cells. Cells were re-suspended in 20 mL of fresh HyQSFM4TransFx293 medium to a final
density of 5 × 10
6 cells/mL and transfected with 2 μg DNA and 4 μg PEI in 125 mL Erlenmeyer flask at 34°C and 37°C. Transfections were done
at 0, 48, and 96 hours post-inoculation. a: total cell density and viability; b: rFVIII activity measured by chromogenic assay; and c: rFVIII
concentration measured by ELISA. Values shown are the averages (mean ± SEM) of the duplicated samples from one representative experiment.
The dotted lines indicate when the re-transfections were done.
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In this study, we evaluated the potential of the transient
transfection technique for rFVIII production. More spe-
cifically, we investigated the effect of different DNA
concentration and repeated transfection at 34° and 37°C
on rFVIII production by human HEK293 cells cultured
in serum-free suspension.
The transfection efficiency largely depends on the for-
mulation of transfection complexes, which usually repre-
sents 10% of the culture volume. The cell number-based
DNA dosage and the DNA:PEI mass ratio are the most
important variables affecting transfection efficiency [17].
A PEI:DNA mass ratio of 2:1 is considered the optimal
ratio for transient transfection of HEK293 cells [12,18],
which is the same cell line than the one used in our
study. Therefore, we kept this PEI:DNA ratio when test-
ing different DNA concentrations for rFVIII protein
production.
For higher polyplex amounts, we observed a decrease
in cell growth. Nevertheless, no significant differences in
transfection efficiency and in the biological activity of
the rFVIII were noticed. It has been suggested that
lower amounts of polyplexes minimize toxic effects of
PEI and also minimize cell aggregation, leading to
higher productivity after transient transfection [19].
Besides, for a repeated transfection approach it is very
important to maintain a high viable cell concentration
during the whole culturing period. When the DNA con-
centration of 0.8 μg/10
6 cells was used, the cell viability
started to decrease at 48 hpt (hours post transfection)
and reached low values at 96 hpt. We thus hypothesized
that it would not be productive to retransfect this cul-
ture. Thus, we applied a DNA concentration of 0.4 μg/
10
6 cells, which presented a satisfactory cell growth and
viability, as the standard condition. This DNA concen-
tration has also the advantage of reduced costs.
The production of rFVIII and the maintenance of its
biological activity are very difficult, especially in serum-
free medium. Whereas the expression of rFVIII in
serum containing medium, which includes vWF (von
Willebrand Factor) that acts as a natural FVIII stabilizer,
usually results in high yields, the expression of this com-
plex protein in serum free medium imposes further
challenges due to the absence of vWF [3]. There is evi-
dence showing that under serum free conditions, rFVIII
binds to the phospholipids on the cell membrane result-
ing in degradation [20]. Therefore, to protect, stabilize
and release rFVIII into the culture medium, the
Figure 3 Profile of nutrient consumption and by-product formation during high-density transfection of Hek293 cells. Cells were re-
suspended in 20 mL of fresh HyQSFM4TransFx293 medium to a final density of 5 × 10
6 cells/mL and transfected using a PEI:DNA ratio of 2:1.
(A) Transfection using 0.4, 0.6, and 0.8 μgDNA/10
6 cells at 37°C; (B) Repeated transfection using 0.4 μgDNA/10
6 cells at 0, 48, and 96 hours post-
inoculation at 37°C and 34°C.
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another approach to solve this problem, Winge [21]
shows that large amounts of active rFVIII could be
released from serum-free recombinant HEK293 cells
through exposure to a solution of high ionic strength.
We thus hypothesized that there is a link between these
observations and what was found concerning the similar
biological activity of rFVIII in the experiments with dif-
ferent DNA concentrations. Although a higher amount
of protein had been produced using 0.4 μgD N A / 1 0
6
cells, the biological activity remained at a similar level;
this could have been due to a superior level of cell
membrane binding and consequent degradation due to
the increased cell concentrations. Strategies to overcome
these challenges will be further developed.
The best condition for rFVIII production was obtained
with repeated transfections at 34°C (Table 1). After 144
hours of culture, almost 50 IU of active rFVIII was pro-
duced. If all the rFVIII protein produced at 34°C
(approximately 400 ng/mL) was active, a biological
activity of 2 IU/mL and a production of 100 IU of
rFVIII could potentially be achieved. This condition also
resulted in the highest cell-specific rFVIII production
rate.
Cells cultured below physiological temperatures have
genetic, molecular, and phenotypic alterations [22]. Cells
cultured under mild hypothermic conditions (30°C to
35°C) have been found to induce an actively regulated
growth reduction in cells within the S or G1 phase of
the cell cycle [23] and an increased rate of recombinant
protein synthesis. Actively metabolizing cells maintain
their growth arrest through inhibiting growth mechan-
isms. In addition to an increase in productivity induced
by growth arrest, cultivation of cells under mild
hypothermic conditions offers other relevant advantages:
extended culture times (lower cell populations reduce
overall nutrient uptake and waste production) [24],
decreased O2 demand [25], reduced intermolecular pro-
duct aggregation [26], increased sensitivity to pH
changes [27,28], and a decreased sensitivity to pro-apop-
totic agents [29,30]. Protein sialylation [24], acidic glyco-
forms [31], and antennary structures [31] are relevant
Figure 4 High-density transfection of Hek293 cells in batch mode (without changing the medium). Cells were re-suspended in 20 mL of
fresh HyQSFM4TransFx293 medium to a final density of 5 × 10
6 cells/mL and transfected with 2 μg DNA and 4 μg PEI in 125 mL Erlenmeyer
flask at 37°C.
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under hypothermic conditions. Beyond to providing a
good nutritional environment for cell growth, complete
replacement of the culture medium provided an ade-
quate culture environment for FVIII expression and
maintenance of biological activity. This finding is not
surprising since, the bioprocesses currently used for
commercial production of rFVIII are based on continu-
ous perfusion or fed-batch bioreactor cultures.
Comparing the rFVIII levels produced in this work
with results reported by other groups is difficult because
most studies provide information on the expression
levels in cell basis (IU/10
6 cells/24 hour) and no infor-
mation is provided on the volumetric concentration and
on the kinetic expression profile, which are needed
when analyzing the scalability of the process. Further-
more, the expression is always performed in static cul-
tures and sometimes in serum-containing medium. The
approaches used to improve rFVIII production focus on
identifying new host cell lines and expression vectors/
promoters to enhance rFVIII expression [15,32-37] or
engineering of the FVIII molecule to prolong its half-life
[38-40]. Other efforts include the development of new
recombinant cell lines and vectors for cell and gene
therapy [41-45].
Recently, Spencer et al. [4] showed some kinetic data
on porcine rFVIII expression in BHK cells while work-
ing with static cultures. Haack et al. [32] performed
transient transfection of full-length and B-deleted rFVIII
p r o d u c t i o ni nH E K 2 9 3 ,C O S ,a n dC H Oc e l l s .T h e
authors presented a kinetic expression profile but the
levels reached were low (around 8-10 ng/mL). Chen et
al. [33] studied the rFVIII transient expression in differ-
ent cell lines (SMMC-7721, A549, Cos-7 and CHO) and
found rFVIII levels in the range of 24 to 201 ng/mL.
The highest expression level was obtained in the CHO
cells. In this work, expression levels were 40 to 50-fold
higher (400 ng/mL) than obtained by Haack et al. [32]
and 2-fold higher than Chen et al. [33].
Previous work describing the transient expression of
rFVIII reported lower yields (see above) and also used
exclusively adherent cells in combination with costly
transfection agents [32,33]. In contrast, suspension-
grown HEK293 cells in combination with PEI-mediated
transfection were used in this work. Whereas the yield
obtained with adherent cells is generally limited by the
cell culture surface area, suspension-grown cell lines
show better and more straightforward scalability. Their
use allows for production at high cell density in shake
flask and continuous bioreactor perfusion cultures to
reach high yields and rescue labile products in the cell
free supernatant. For the development of an efficient
and effective production process, the scale-up should
ideally target an increased culture volume while
achieving an enhanced volumetric productivity (such as
attained here through production in high cell density
suspension cultures); in contrast, only a higher number
of production vessels or a larger surface area, as often
done for adherent cultures (from T-flasks to roller bot-
tles and cell factories), represents a sub-optimal scale-
up. We have previously shown that transient transfec-
tion based processes can be successfully scaled up to 3
L stirred tank reactors using perfusion bioreactor opera-
tion [19]. We thus anticipate that scaling up rFVIII pro-
duction from small scale medium replacement to
continuous perfusion operation using an acoustic cell
filter would be straightforward and should result in
comparable protein yields.
Currently, there are no FDA-approved recombinant
proteins generated by large-scale transient transfection.
Several issues need to be addressed before the repeated
transient transfection method can be implemented in a
manufacturing environment. For example, batch to
batch product consistency and process robustness
remain to be demonstrated at large scale [46]. Other
concerns comprise the cost-effective generation of suffi-
cient amounts of plasmid DNA [13]. Although it seems
to remain to some extent unclear what quality attributes
such DNA would need to fulfill the use in commercial
manufacturing, the challenges concerning high-yield
plasmid DNA production for large scale transient trans-
fection have been extensively addressed in the literature.
For example, these include the removal of E. coli DNA
and endotoxins [47-50]. In agreement with Geisse [51],
the generation of recombinant DNAs for large scale
applications should not be limited by current standard
E. coli expression and purification techniques. Usually,
from 2 to 3 L of bacterial cultures, 10-20 mg of plasmid
DNA can be obtained. At commercial scale, this process
can be easily adapated to bioreactor production to
further improve the productivity. Indeed, Cheng et al
reported the production of 1.5 g plasmid DNA from 3 L
fermentation broth of E. coli in a cost effective manner,
suitable for scaling up to meet the large demand of
DNA [49]. All of these issues then need to be evaluated
and weighed against the laborious and time-consuming
generation of stable cell lines which could eventually
lead to improved process yields. Overall, we do need to
highlight that the ever-increasing number of publica-
tions on transient transfection technologies employed
for recombinant protein production reflects the success
of this approach in the past decade [51].
Conclusion
To our knowledge this is the first study describing a
rFVIII production method based on transient transfec-
tion in suspension serum-free cultures that can be oper-
ated at large scale. This method can be used to easily
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time to be further used in functional characterization
and pre-clinical studies. Work is in progress to further
optimize the process and demonstrate its scalability.
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